Critical care (London, England), 2018-12, Vol.22 (1), p.343-343, Article 343
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
- Ist Teil von
- Critical care (London, England), 2018-12, Vol.22 (1), p.343-343, Article 343
- Ort / Verlag
- England: BioMed Central Ltd
- Erscheinungsjahr
- 2018
- Quelle
- Springer Online Journals【Remote access available】
- Beschreibungen/Notizen
- Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1364-8535eISSN: 1466-609X, 1364-8535DOI: 10.1186/s13054-018-1958-4Titel-ID: cdi_doaj_primary_oai_doaj_org_article_f67bf3dbc05f48c084cbe29fdc19aaee
- Format
- –
- Schlagworte
- Administration, Inhalation, Amikacin, Amikacin - pharmacology, Amikacin - therapeutic use, Analysis, Anti-Bacterial Agents - pharmacology, Anti-Bacterial Agents - therapeutic use, Bacteris gramnegatius, Care and treatment, Clinical trials, Gram-negative bacteria, Gram-Negative Bacteria - drug effects, Gram-negative bacterial infections, Humans, Infeccions respiratòries, Intensive care units, Intensive Care Units - organization & administration, Pneumonia - drug therapy, Pseudomonas aeruginosa, Pseudomonas aeruginosa - drug effects, Respiratory infections, Review, Risk factors, Unitats de cures intensives, Ventilator-associated pneumonia